An interventional study of Losartan and Placebo in Healthy, sponsored by University of Electronic Science and Technology of China. Recruiting at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-11.
Sponsored by University of Electronic Science and Technology of China · Not applicable, Interventional, and Basic science
The main aim of the present study is to investigate the effects of orally administered losartan on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.
Animal models and initial findings in humans suggest a role of the angiotensin II antagonist losartan in socio- emotional processes. At the same time, the visual system's remarkable ability to perceive and interpret impending threats, notably through the "looming" phenomenon- a distinct pattern of optical expansion on the retina as objects approach, theoretically allows for precise estimation of the time-to-collision (TTC). It was demonstrated that the affective content of looming stimuli influences perceived TTC, with threatening objects judged as approaching sooner than non-threatening objects, hinting at a nuanced interaction between emotional valence and temporal perception. Within this context the present study aims to examine whether angiotensin II blockade via Losartan modulates the perception of time-to-collision towards threatening and non-threatening stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of losartan (50 mg) or placebo before performing a looming fear task 90 minutes after administration. The task paradigm will encompass threatening (butterfly, rabbit) and non-social (spider, snake) stimuli to examine the emotion-specific effects of losartan.
University of Electronic Science and Technology of China is the lead sponsor of 109 studies on the registry; 35 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug:Losartan
Drug: Losartan
Drug: Placebo
Drug: Placebo
Administration of losartan tablets (50 mg)
Also known as: Cozaar
Administration of placebo tablets
Also known as: Placebo treatment
Ratio of judged-time-to-collision to actual-time-to-collision for threatening versus non-threatening stimuli after losartan administration
Comparison of the ratio between the judged time to collision and the actual time to collision between the treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.
Time frame: 120 minutes - 150 minutes after treatment
First saccade latency(ms) for threatening versus non-threatening stimuli after losartan administration
Comparison of first saccade latencies between treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.
Time frame: 120 minutes - 150 minutes after treatment
Fixation duration(ms) for threatening versus non-threatening stimuli after losartan administration
Comparison of mean fixation durations between treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.
Time frame: 120 minutes - 150 minutes after treatment
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Electronic Science and Technology of China